Drugs / CAIX-LT-BCH
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07590310 | Mar 2025 → Dec 2026 expected | kidney cancer | Peking University Cancer Hospital & Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAIX-LT-BCH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07590310 ↗ |
| Modality | Diagnostic / imaging agent | “PET probes were prepared by radiolabeling with 68Ga or 18F, and their diagnostic efficacy for renal cancer was investigated.” NCT07590310 ↗ |
| Route | Intravenous | “68Ga/18F-CAIX-LT-BCH (0.05-0.1 mCi/kg) is intravenously administered” NCT07590310 ↗ |